Comprehensive supply chain solutions for the Life Sciences
CryoPortal Login
  • English
    • Español (Spanish)
    • Français (French)
    • 日本語 (Japanese)
    • 简体中文 (Chinese)
Cryoport Systems logo
  • Industry Expertise
    • Cell Therapy
    • Gene Therapy
    • Biologics
    • Support by Development Phase
      • Pre-Clinical Programs
      • Phase I Clinical Programs
      • Phase II Clinical Programs
      • Phase III Clinical Programs
      • Commercial Programs
    • Reproductive Medicine
      • Intended Parents
      • Clinics
    • Animal Health
      • Animal Pharmaceuticals
      • Livestock Management
      • Veterinary Care
  • Trusted Solutions
    • Shipping Systems
      • Cryogenic (below -150°C) Shipping Systems
        • Cryoport Express® Cryogenic Standard Shipping System
        • Cryoport Express® Cryogenic Combo Shipping System
        • Cryoport Express® Cryogenic HV3 Shipping System
        • Cryomax® Cryogenic Shipping System
      • Ultra Cold (-60 to -80°C) Shipping Systems
        • Cryoport Elite® Ultra Cold
      • Refrigerated (2 to 8°C) and CRT (15 to 25°C) Shipping Systems
        • Cryoport Express® C3™ Shipping System
      • Cryoport Accessories
        • Cryoport Safepak® System
    • Transportation
      • Cryoshuttle®
    • BioServices
      • Biostorage Solutions
      • Kit Production
      • Secondary Packaging and Labelling
      • Clinical Sample Management
      • Regulatory & QP Services
    • Consulting Services
      • Shipping Risk Assessment and Shipping Lane Qualification
      • Shipping System and Packaging Performance Qualification
      • Custom Packaging and Accessory Development
    • IntegriCell® Cryopreservation
  • Technology
    • Cryoportal®
    • Veri-Clean®
    • Chain of Compliance®
    • Tec4med
    • Custom Packaging and Accessory Development
  • About Us
    • Our People
    • Management
    • Quality
    • Careers
    • Cryoport’s Family of Companies
  • Resources
    • Events
    • Supply Chain Blog
    • Company News & Articles
    • Brochures and Spec Sheets
    • Instructions
    • Order Forms
    • White Papers and Case Studies
    • Videos/Webinars
    • Reference Materials
      • Cryoportal® 2 Training Materials
      • Validation Package Request
      • Data Station Direction & Validation
      • Quality Change Notification Request
      • Certifications
      • Smartpak II™ Airline Authorizations
  • Contact Us
    • Request a Quote
    • Locations
  • Investor Relations
CryoPortal Login
Request Info
Request a Quote
Request a Quote
Request Info Request a Quote

Articles Archives

Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award for Cold Chain Logistics at APCGTEA 2026
Articles
07/07/2026

Cryoport Systems Wins Best Cell & Gene Therapy Supplier Award for Cold Chain Logistics at APCGTEA 2026

Cryoport Systems is pleased to announce that we have been named Best Cell & Gene Therapy Supplier – Cold Chain Logistics at the 2026 Asia-Pacific Cell & Gene Therapy Excellence Awards (APCGTEA). This recognition carries special meaning as it reflects the voice of the global advanced therapies community.

Read More

Read More
Scaling Animal Health Programs Shouldn’t Mean Requalifying Your Supply Chain
Animal Pharmaceuticals
07/07/2026

Scaling Animal Health Programs Shouldn’t Mean Requalifying Your Supply Chain

Animal health programs tend to reveal their logistics weaknesses at the point of growth. A process that feels manageable when a therapy, vaccine, biologic, or reproductive material is moving between a limited number of familiar sites can become difficult to defend once the same program expands across facilities, regions, partners, or countries. The science may be ready to scale, but the operational framework often has to prove that it can scale with it.

Read More

Read More
Lane Qualification Reduces Risk Before Shipments Move
Animal Health
05/21/2026

Lane Qualification Reduces Risk Before Shipments Move

Animal health biopharmaceutical programs put pressure on logistics networks in ways that standard route planning doesn’t always capture. Vaccines may move in defined seasonal windows, while monoclonal antibodies (mAbs), cell-based therapies, biologics, and other sensitive materials may move through channels with different timing constraints. Some shipments are tied to manufacturing release, others are tied to clinical study schedules, and still others are fitting into regional disease control programs or veterinary network demand.

Read More

Read More
Validated Shipping Systems are the Foundation of Risk-Mitigated Animal Health Logistics
Animal Health
04/21/2026

Validated Shipping Systems are the Foundation of Risk-Mitigated Animal Health Logistics

Animal health logistics are entering a phase where variability is no longer tolerable. Vaccines, biologics, reproductive materials, and advanced therapies are sensitive to critical parameters like temperature and handling conditions, and as regulatory expectations continue to move toward tighter controls and clearer documentation, shipping has become so much more than a support function.

Read More

Read More
The Visibility and Traceability Animal Health Programs Need
Animal Health
03/19/2026

The Visibility and Traceability Animal Health Programs Need

Temperature-sensitive materials now move through animal health programs in far greater volumes, and that shift has raised the bar for how their transit needs to be documented. Teams responsible for oversight want documentation that reflects actual handling conditions from origin to delivery, with enough detail to support a clear assessment of risk. While the regulatory environment for animal health lags behind that for human health, programs are increasingly expected to provide records that reflect the actual conditions and custody of the material throughout transit.

Read More

Read More
Temperature-Controlled Shipping: A Lifeline for Animal Health Companies
Animal Pharmaceuticals
09/16/2025

Temperature-Controlled Shipping: A Lifeline for Animal Health Companies

For animal health companies, the success of a product is determined long before it reaches the veterinary clinic, farm, or research facility. No matter how innovative a vaccine, biologic, or next-gen therapy may be, its ultimate impact depends on maintaining its integrity during transportation. Temperature-controlled logistics are no longer a back-office concern, they have become a core element of success that impacts product efficacy, regulatory compliance, and even operational efficiency.

Read More

Read More
What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team
Industry Insights
07/22/2025

What’s Next for the CGT Industry? Mid-Year Check-In from the Leadership Team

We’re halfway through 2025, and the cell and gene therapy (CGT) landscape stands at a crossroads. Innovation continues to advance, yet the infrastructure required to support commercialization remains under pressure. To assess the current state of the industry and what’s ahead, Cryoport Systems gathered candid insights from our internal leaders across functions, from product development and commercial strategy to operations and client engagement.

Read More

Read More
Celebrating Logistics, the Unsung Hero in Cell and Gene Therapy Innovation
Managing the Cold Chain
06/28/2025

Celebrating Logistics, the Unsung Hero in Cell and Gene Therapy Innovation

Every National Logistics Day offers a chance to recognize the systems and people that quietly power the innovation engine for Cell and Gene Therapy (CGT). While logistics frequently brings to mind images of trucks and warehouses, cardboard boxes, and tracking numbers, for CGT developers, it’s the infrastructure that protects innovation and ensures that time-sensitive, potentially life-changing treatments reach patients intact and on time.  At Cryoport Systems, logistics has never been just about transportation. It’s about Enabling the Outcome™.

Read More

Read More
Bridging the Gaps: How Cryoshuttle® Enhances First and Last Mile Resilience
Navigating Logistics
06/27/2025

Bridging the Gaps: How Cryoshuttle® Enhances First and Last Mile Resilience

For advanced therapies, the most vulnerable parts of the transportation journey aren’t always the longest. In fact, the greatest risks often occur in the shortest distances. While intercontinental transport and customs clearance are well-known hurdles, both the first and last mile remain highly vulnerable to disruption.  Cryoport Systems developed our Cryoshuttle® local pickup and delivery services to help close the gap between global transport lanes and local handling environments.

Read More

Read More
Load More

Categories

  • All (58)

Tags

  • Asia
  • ATMPs
  • Biologics
  • Biosecurity
  • BioServices
  • Biostorage
  • Cell Therapy
  • Cold Chain Management
  • Commercialization
  • Cryopreservation
  • Europe
  • Gene Therapy
  • Global Supply Chain Management
  • International Shipping
  • Risk Mitigation
  • Supply Chain Management

Subscribe to our newsletter

Never miss another update! Join our mailing list for all the latest news, events, and announcements.

  • Clinical Trial icon Trusted with 766 clinical trials
  • Approved therapies icons Supporting 21 approved therapies
  • Quality icon Robust quality standards
  • Client service icon 24/7/365 support team
  • About Us
  • Industries
  • Solutions
  • Resources
  • Technology & Innovation
  • Contact Us
  • About Us
  • Industries
  • Solutions
  • Resources
  • Technology & Innovation
  • Contact Us
Cryoport Systems logo
  • Privacy Policy
  • Terms of Use
  • Careers
Request a Quote
  • youtube
  • twitter
  • linkedin
Cryoport Systems logo

© 2026 Cryoport Systems, LLC. All rights reserved.
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC

  • youtube
  • twitter
  • linkedin